Postgraduate research

Cancer Studies

Cancer prevention

Professor Karen Brown

  • Preclinical and early clinical development of novel cancer chemopreventive agents
  • Identification and development of novel biomarkers of cancer risk, prognosis and chemopreventive/chemotherapeutic agent efficacy

Professor Don J. L. Jones

  • Translation of candidate biomarkers to clinical use.
  • Use of high resolution LC-MS in the discovery and verification of biomarkers.
  • Investigation of protein quantification using Ion mobility.
  • Translation of candidate biomarkers to clinical use.
  • Use of high resolution LC-MS in the discovery and verification of biomarkers.
  • Investigation of protein quantification using Ion mobility.

Dr Cristina Tufarelli

  • Determine which repetitive elements are active in precancerous and cancerous cells
  • Understanding what causes activation of repetitive elements
  • Establish activation of which repetitive elements plays functional roles in cancer
  • Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy

Dr Ning Wang

  • Identification of therapeutic targets and biomarkers by exploring glucose metabolism (glycolysis, glycosylation, and purinergic signalling) in cancer initiation and metastasis.
  • Development and implementation of novel pre-clinical models (in vivo) to advance both basic and translational cancer research.
  • Examination of the effects of physical exercise on musculoskeletal disorders, with a focus on cancer-induced bone disease, osteoporosis, and osteoarthritis.

Cancer survivorship and treatment effects

Dr Esther Moss

  • Analysis of circulating endometrial cancer biomarkers through liquid biopsy
  • Molecular profiling for improved stratification to immunotherapies
  • Robotic surgery for management of endometrial cancer
  • Patient-initiated follow up for low-risk endometrial cancer
  • Use of ex-vivo models for personalising therapies

Dr Tim Rattay
  • Personalising breast cancer treatment according to predicted toxicity
  • Radiogenomics and biomarkers
  • Breast surgery and reconstuction
  • Patients' views on breast cancer treatment and predictive testing

Liquid biopsy for early detection and stratification of cancer

Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies
  • Antibody therapy of lymphoid malignancies
  • Development and assessment of novel agents for therapy of B-cell malignancies

Dr David Guttery

  • Analysis of circulating cancer biomarkers through liquid biopsy
  • Molecular approaches to aid early detection of cancer
  • Molecular mechanisms of resistance to targeted therapy
  • Utility of artificial intelligence for early detection and improving therapy stratification

Dr Esther Moss

  • Analysis of circulating endometrial cancer biomarkers through liquid biopsy
  • Robotic surgery for management of endometrial cancer
  • Patient-initiated follow up for low-risk endometrial cancer
  • Use of ex-vivo models for personalising therapies

Professor Jacqui Shaw

  • Analysis of circulating cancer biomarkers through liquid biopsy
  • Molecular approaches to aid early detection of cancer
  • Molecular mechanisms of resistance to targeted therapy

Personalised treatment in B cell malignancies

Dr Matt Ahearne

  • Developing new diagnostic and therapeutic approaches in T-cell lymphoma
  • Targeting the microenvironment in B-cell lymphoma

Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies
  • Antibody therapy of lymphoid malignancies
  • Development and assessment of novel agents for therapy of B-cell malignancies

Dr Harriet Walter

  • Delivery of Phase I portfolio across haematological malignancies and solid tumours
  • Therapeutic drug development
  • Development and assessment of novel agents in the treatment of B-cell malignancies

Personalised medicine

Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies
  • Antibody therapy of lymphoid malignancies
  • Development and assessment of novel agents for therapy of B-cell malignancies

Professor Dean Fennell

  • Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers

Dr David Guttery

  • Analysis of circulating cancer biomarkers through liquid biopsy
  • Molecular approaches to aid early detection of cancer
  • Molecular mechanisms of resistance to targeted therapy
  • Utility of artificial intelligence for early detection and improving therapy stratification

Professor Don J. L. Jones

  • Translation of candidate biomarkers to clinical use.
  • Use of high resolution LC-MS in the discovery and verification of biomarkers.
  • Investigation of protein quantification using Ion mobility.
  • Translation of candidate biomarkers to clinical use.
  • Use of high resolution LC-MS in the discovery and verification of biomarkers.
  • Investigation of protein quantification using Ion mobility.

Professor Bruno Morgan

  • Imaging applications to monitor drug therapy
  • Imaging in cancer research trials including CT, MRI, Ultrasound and PET-CT

Dr Tim Rattay

  • Personalising breast cancer treatment according to predicted toxicity
  • Radiogenomics and biomarkers
  • Breast surgery and reconstuction
  • Patients' views on breast cancer treatment and predictive testing

Professor Jacqui Shaw

  • Analysis of circulating cancer biomarkers through liquid biopsy
  • Molecular approaches to aid early detection of cancer
  • Molecular mechanisms of resistance to targeted therapy

Dr Harriet Walter

  • Delivery of Phase I portfolio across haematological malignancies and solid tumour
  • Therapeutic drug development
  • Development and assessment of novel agents in the treatment of B-cell malignancies

Dr Ning Wang

  • Identification of therapeutic targets and biomarkers by exploring glucose metabolism (glycolysis, glycosylation, and purinergic signalling) in cancer initiation and metastasis.
  • Development and implementation of novel pre-clinical models (in vivo) to advance both basic and translational cancer research.
  • Examination of the effects of physical exercise on musculoskeletal disorders, with a focus on cancer-induced bone disease, osteoporosis, and osteoarthritis.

Pre clinical models enabling drug and biomarker discovery

Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies
  • Antibody therapy of lymphoid malignancies
  • Development and assessment of novel agents for therapy of B-cell malignancies

Dr Gareth Miles

  • Development of Ex-vivo patient relevant drug testing platforms
  • Assessment of novel agents for therapy of solid malignancies using ex vivo models
  • Identification and development of novel biomarkers of anticancer drugs using ex vivo models

Dr Esther Moss

  • Analysis of circulating endometrial cancer biomarkers through liquid biopsy
  • Molecular profiling for improved stratification to immunotherapies
  • Robotic surgery for management of endometrial cancer
  • Patient-initiated follow up for low-risk endometrial cancer
  • Use of ex-vivo models for personalising therapies

Professor Catrin Pritchard

  • Mechanisms of RAS/RAF oncogene induced tumour development
  • RAF/MAPK signalling in normal and cancer cells
  • Ex vivo patient relevant drug testing platforms

Dr Cristina Tufarelli

  • Determine which repetitive elements are active in precancerous and cancerous cells
  • Understanding what causes activation of repetitive elements
  • Establish activation of which repetitive elements plays functional roles in cancer
  • Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy

Dr Ning Wang

  • Identification of therapeutic targets and biomarkers by exploring glucose metabolism (glycolysis, glycosylation, and purinergic signalling) in cancer initiation and metastasis.
  • Development and implementation of novel pre-clinical models (in vivo) to advance both basic and translational cancer research.
  • Examination of the effects of physical exercise on musculoskeletal disorders, with a focus on cancer-induced bone disease, osteoporosis, and osteoarthritis.

Back to top
MENU